NCT05136898View on ClinicalTrials.gov

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
Interventions
DRUG

UGN-102

UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.

Trial Locations (5)

23235

Virginia Urology, Richmond

27408

Medication Management, Greensboro

35209

Urology Centers of Alabama (UCA), Homewood

37209

Urology Associates, P.C., Nashville

46202

Indiana University School of Medicine, Indianapolis

All Listed Sponsors
lead

UroGen Pharma Ltd.

INDUSTRY

NCT05136898 - Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | Biotech Hunter | Biotech Hunter